Evidence map›Paper›PMID 32099037›Full record

Trial reportLeukemia2020

A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia.

Prithviraj Bose, Srdan Verstovsek, Jorge E Cortes, Susan Tse, Yvonne Gasior, Nitin Jain, Elias J Jabbour, Zeev Estrov, Yesid Alvarado, Courtney D DiNardo and 14 more

Abstract readClinical Trial, Phase IClinical Trial, Phase IILetter
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Leukemia, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 1 pooled it
4.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 1 institution in 1 country.

Prithviraj BoseDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-4343-5712
Srdan VerstovsekDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jorge E CortesDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Susan TseDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Yvonne GasiorDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Nitin JainDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Elias J JabbourDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Zeev EstrovDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Yesid AlvaradoDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Courtney D DiNardoDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-9003-0390
Naveen PemmarajuDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Steven M KornblauDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-5990-9548
Tapan M KadiaDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-9892-9832
Naval G DaverDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Kiran NaqviDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Nicholas J ShortDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Lucia MasarovaDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
John VillarealDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Sherry A PierceDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Graciela Nogueras-GonzalezDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-6350-2206
Xuelin HuangDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Guillermo Garcia-ManeroDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Hagop M KantarjianDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Farhad RavandiDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. fravandi@mdanderson.org.
The University of Texas MD Anderson Cancer Center · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsDecitabineDose-Response Relationship, DrugFemaleHumansLeukemia, Myeloid, AcuteMaleMiddle AgedMyeloproliferative DisordersNeoplasms, Second PrimaryNitrilesPyrazolesPyrimidinesDecitabineNitrilesPyrazolesPyrimidinesruxolitinib

Identifiers

PMID32099037
PMCPMC12136008
OpenAlexW3007649801

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.